SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in pre-clinical and clinical compound development for the treatment of central nervous system disorders. The company's innovative approach leverages the therapeutic potential of cannabinoids and pairs them with established drugs to extend or enhance their efficacy. SciSparc's portfolio includes drug candidates targeting conditions such as Tourette syndrome, obstructive sleep apnea, and Alzheimer’s disease, highlighting its focus on addressing unmet medical needs in neurological health. Operating in a highly regulated industry, the company ensures adherence to clinical and regulatory standards, which shapes its progress in drug development and approval pipelines. With a commitment to improving patient quality of life, SciSparc uses scientific research to drive breakthroughs in pharmaceutical treatments. SciSparc’s work has ramifications in both the healthcare and biotech sectors, contributing to the broader understanding of cannabinoid applications in medicine.